Literature DB >> 21039730

Determinants of plasma PTH and their implication for defining a reference interval.

Lars Rejnmark1, Peter Vestergaard, Lene Heickendorff, Leif Mosekilde.   

Abstract

BACKGROUND: To improve the diagnostic sensitivity of PTH measurements, more data on the upper limit of the reference interval for PTH levels were requested at a recent international consensus conference. As PTH levels vary inversely with plasma 25-hydroxyvitamin D (25OHD) levels and as vitamin D insufficiency is widespread, particular attention should be given to the influence of low vitamin D levels on the PTH reference interval. AIM, DESIGN AND METHODS: In a cross-sectional design, including 2316 women aged 17-84, we determined 95% reference interval using a nonparametric approach and studied the effects of potential predictors on plasma PTH levels.
RESULTS: PTH was a positive function of age, body weight and BMI and inversely associated with total daily calcium intake, smoking, plasma calcium levels and 25OHD levels, all of which explained 16% of the variability in plasma PTH levels. The threshold value for 25OHD levels below which PTH levels started to rise was 82 nmol/l. Plasma PTH levels varied inversely with the seasonal variations in 25OHD levels. Mean PTH level was 4·1 pmol/l with a reference interval equal to 2·0-8·6 pmol/l. Restricting the population in whom the reference interval was calculated to only women with 25OHD levels above 30 or 100 nmol/l lowered the upper limit of the reference interval to 8·4 and 7·1 pmol/l, respectively. Similar, stratification according to age, body mass index, smoking and calcium intake had only minor impact on the reference interval.
CONCLUSION: Indices with known effects on plasma PTH levels have only a minor impact on the upper levels of the normative reference interval in women with intact renal function.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21039730     DOI: 10.1111/j.1365-2265.2010.03894.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  19 in total

Review 1.  How the reference values for serum parathyroid hormone concentration are (or should be) established?

Authors:  J-C Souberbielle; F Brazier; M-L Piketty; C Cormier; S Minisola; E Cavalier
Journal:  J Endocrinol Invest       Date:  2016-10-01       Impact factor: 4.256

2.  Primary hyperparathyroidism: just how 'primary' is it really?

Authors:  Richard Quinton; Stephen G Ball; John Sayer; Simon H S Pearce
Journal:  Ther Adv Endocrinol Metab       Date:  2010-10       Impact factor: 3.565

3.  Parathyroid hormone reflects adiposity and cardiometabolic indices but not bone density in normal men.

Authors:  Emma O Billington; Greg D Gamble; Ian R Reid
Journal:  Bonekey Rep       Date:  2016-12-07

4.  Establishment of a normal reference value of parathyroid hormone in a large healthy Chinese population and evaluation of its relation to bone turnover and bone mineral density.

Authors:  M Li; F Lv; Z Zhang; W Deng; Y Li; Z Deng; Y Jiang; O Wang; X Xing; L Xu; W Xia
Journal:  Osteoporos Int       Date:  2016-01-05       Impact factor: 4.507

5.  Reduced parathyroid hormone-stimulated 1,25-dihydroxyvitamin d production in vitamin d sufficient postmenoposual women with low bone mass and idiopathic secondary hyperparathyroidism.

Authors:  Elizabeth A Streeten; Amy S Rogstad; Kristin M Flammer; Kiarash Zarbalian; Kathleen Ryan; Mara Horwitz; Michael F Holick; John Shelton
Journal:  Endocr Pract       Date:  2013 Jan-Feb       Impact factor: 3.443

6.  Clinical characteristics influence in vitro action of 1,25-dihydroxyvitamin D(3) in human marrow stromal cells.

Authors:  Shuanhu Zhou; Julie Glowacki; Sung Won Kim; Jochen Hahne; Shuo Geng; Stefan M Mueller; Longxiang Shen; Ilan Bleiberg; Meryl S LeBoff
Journal:  J Bone Miner Res       Date:  2012-09       Impact factor: 6.741

7.  Genetic Variants Associated with Circulating Parathyroid Hormone.

Authors:  Cassianne Robinson-Cohen; Pamela L Lutsey; Marcus E Kleber; Carrie M Nielson; Braxton D Mitchell; Joshua C Bis; Karen M Eny; Laura Portas; Joel Eriksson; Mattias Lorentzon; Daniel L Koller; Yuri Milaneschi; Alexander Teumer; Stefan Pilz; Maria Nethander; Elizabeth Selvin; Weihong Tang; Lu-Chen Weng; Hoi Suen Wong; Dongbing Lai; Munro Peacock; Anke Hannemann; Uwe Völker; Georg Homuth; Matthias Nauk; Federico Murgia; Jack W Pattee; Eric Orwoll; Joseph M Zmuda; Jose Antonio Riancho; Myles Wolf; Frances Williams; Brenda Penninx; Michael J Econs; Kathleen A Ryan; Claes Ohlsson; Andrew D Paterson; Bruce M Psaty; David S Siscovick; Jerome I Rotter; Mario Pirastu; Elizabeth Streeten; Winfried März; Caroline Fox; Josef Coresh; Henri Wallaschofski; James S Pankow; Ian H de Boer; Bryan Kestenbaum
Journal:  J Am Soc Nephrol       Date:  2016-12-07       Impact factor: 14.978

8.  PTH Assays: Understanding What We Have and Forecasting What We Will Have.

Authors:  Jose Gilberto H Vieira
Journal:  J Osteoporos       Date:  2012-04-03

9.  Factors Associated with Bone Mineral Density and Bone Resorption Markers in Postmenopausal HIV-Infected Women on Antiretroviral Therapy: A Prospective Cohort Study.

Authors:  Christa Ellis; Herculina S Kruger; Michelle Viljoen; Joel A Dave; Marlena C Kruger
Journal:  Nutrients       Date:  2021-06-18       Impact factor: 5.717

10.  Differences between hospitals in attainment of parathyroid hormone treatment targets in chronic kidney disease do not reflect differences in quality of care.

Authors:  Mieke J Peeters; Arjan D van Zuilen; Jan A J G van den Brand; Peter J Blankestijn; Marc A G J ten Dam; Jack F M Wetzels
Journal:  BMC Nephrol       Date:  2012-08-06       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.